Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00. Following the completion of the sale, the chief executive officer now owns 520,661 shares of the company’s stock, valued at approximately $9,080,327.84. This trade represents a 9.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total value of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.32, for a total value of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total transaction of $350,839.00.

Centessa Pharmaceuticals Trading Down 2.2 %

Shares of Centessa Pharmaceuticals stock opened at $17.16 on Friday. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -11.22 and a beta of 1.52. The business has a 50-day moving average price of $16.64 and a 200-day moving average price of $13.57. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $6.65 and a twelve month high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC acquired a new stake in Centessa Pharmaceuticals during the second quarter valued at $4,064,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at about $1,609,000. Ally Bridge Group NY LLC acquired a new position in Centessa Pharmaceuticals during the third quarter worth $4,951,000. Driehaus Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 89.5% in the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after purchasing an additional 987,997 shares during the period. Finally, GSA Capital Partners LLP increased its holdings in shares of Centessa Pharmaceuticals by 66.1% during the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after buying an additional 37,275 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of a number of recent research reports. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Guggenheim boosted their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. BMO Capital Markets raised their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Finally, Jefferies Financial Group boosted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.